Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram to prevent post-stroke depression and dementia after acute MCA infarction
2005-005266-37Phase 2Active
- Sponsor
- Central Institute of Mental Health
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and Dementia comparing Escitalopram (Cipralex) with Placebo (2 arms). Primary endpoint: Incidence of post-stroke depression at 180 days. Started Jan 2006; status: active.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)Dementia
Beyond the preview
Go deeper on 2005-005266-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005266-37.